locations and sprains represented 37%, 27% were mainly contusions/abrasions, 23% had open wounds, and <1% major abdominal injury. The visit reason codes for the remaining cases included pain, other symptoms and conditions. Mean duration of ED visit was 2.3 hours (median: 1.8). Mean cost per ED visit was $460 (median: $325) for those treated and released and $560 for those admitted (median: $427). On average, those admitted spent 3 days (median: 2) in the hospital at a cost of $8375 (median: $6340). CONCLUSIONS: Most bicycle related injuries occurred in children or young adults, in the early evening, involved only the cyclist and could be managed in the ED.

PHP11
PRESCRIBING PATTERNS OF CIPROFLOXACIN AND LEVOFLOXACIN IN AN ITALIAN GERIATRIC HOSPITAL
Busca MR1, Berto P2, Benato G3, Cofani C4, Berre F5, Borgia L6, Di Muzio M7
1Pbe Consulting, Milano, Italy; 2Pbe Consulting, Verona, Italy; 3Bayer Spa, Milano, Italy; 4In.R.C.A. Ospedale, Ancona, Italy; 5Università di Camerino, Falconara Marittima, Italy
OBJECTIVES: Drug costs represent a considerable cost item in the overall hospital budget. Within drug costs, oral and injectable antibiotics are indeed one of the most relevant sources of expenditure. This analysis is focused on the comparison between the actual per patient consumption of antibiotics and the Defined Daily Dose (DDD) which is frequently used as an indicator for inclusion of a drug in the Hospital Formulary and subsequent purchase. METHODS: This research was based on the analysis of the Antibiotics Request Forms (ARF’s), which were forwarded by the Hospital Wards to the Pharmacy in the Geriatric Hospital “U. Sestilli”, Ancona. The analysis was focused on the daily per patient consumption (Prescribed Daily Doses, PDD) of antibiotic treatments as compared to the DDD, and on its cost (considering officially published prices and hospital discounts). RESULTS: In the period February–May, 2003, 2350 ARF’s were filed, referring to prescriptions of antibiotics. Of these, 1942 were eligible for analysis and concerned 976 patients. Total expenditure for antibiotics in such period was 63,727€; 25% of this was due to the fluoroquinolones currently included in the Hospital Formulary (ATC J01MA); ciprofloxacin and levofloxacin. By comparing PDD’s with DDD’s, and assuming equal to one the exact correspondence between PDD and DDD of each drug, in 75% of prescriptions PDD’s did not correspond to DDD’s. In particular, the PDD/DDD rate resulted 0.68 for injectable ciprofloxacin, and 1.1 for injectable levofloxacin: similarly, considering oral formulations, the two rates were respectively 0.79 and 1.28. CONCLUSIONS: According to the prescription practice of this Hospital and to the type of patients seen, the inclusion in Hospital Formulary and purchase of antibiotics based on the DDD’s might be misleading and could result into an incoherent management of Pharmacy stock and financial assets.

PHP12
COST VARIANCES IN G-DRG GROUPS. THE EXAMPLE OF RH BMP-2 IN SPINE FUSION SURGERY
Meisel H1
BG-Clinic Bergmannstrost, Halle, Germany
OBJECTIVES: The new G-DRG hospital payment system came into effect in 2003. For a fully functional DRG-payment system it is important that DRG groups are cost homogenous. METHODS: To show the impact of innovations on the cost homogeneity of a DRG group, a cost study has been performed as a sub-study of a clinical safety and feasibility analysis. RESULTS: We used the bone growth protein rhBMP-2 (not yet approved for Spine indication in Europe) additional to standard fusion for spine surgery in 18 cases. RhBMP-2 has the potential to reduce complication rates, avoids iliac crest bone graft harvesting and associated morbidities and ensures earlier return to work. The relevant DRG for fusion procedures in our patient group—with or without the usage of rhBMP-2—is I09B, relative weight 2.875 and average costs of 8313.94€. Average costs have been assessed in 536 patients. In our study we have assessed the cost for spine fusions with and without the usage of rhBMP-2. All costs have been calculated according to InEK calculations rules. Average cost were in the none rhBMP-2 group 8388.41€ with average implant costs of 2576.17€. The results reflect very well cost homogenity in the DRG group. Usage of rhBMP-2 adds significant drug cost (3422€). No significant other cost offsets apply. A total cost increase of 40.79% leads to an unacceptable high cost variance in the I09B. CONCLUSIONS: Based on this data one could conclude that specialized hospital wards in spine surgery who attract more difficult cases will be discriminated in the G-DRG system as they will more often have to use innovative high price drugs or medical devices. An expanded list of supplementary fees for high cost innovative technologies could help to reduce the cost variance within one DRG without the need to further differentiate DRG groups.

PHP13
THE HOSPITAL DIAGNOSTIC THERAPEUTIC PATHWAY OF PATIENTS AFFECTED BY CRITICAL ISCHEMIA OF THE LOWER LIMBS WHICH IS UNRESPONSIVE TO REVASCULARIZATION
Ponzzi P1, Magnoni F2, Scarpa F1, Caprari F3, Pedrini L4
1Fondazione Medtronic Italia, Milano, Italy; 2Ospedale Maggiore, Bologna, Italy
OBJECTIVES: Critical leg ischemia affects between 1.5 and 5% of the population over 50 years old. Before opting for limb amputation, two alternative therapies can be carried out: drug therapy with prostanoid or Spinal Cord Stimulation (SCS). This project, developed in the department of vascular surgery of the Ospedale Maggiore in Bologna, was aimed at evaluating the annual impact of these two treatments on department budget. The annual impact of a therapy on department budget is defined as the difference between the cost of production and the DRG. METHODS: The therapies cost of production was assessed through an Activity Based Management (ABM) and Activity Based Costing (ABC) approach. Activities were identified by informal interviews with all hospital staff involved in the treatment process. Costs were assessed by analyzing accounting data supplied by the hospital administrative services. RESULTS: The SCS pathway consists of two 3-days hospitalizations. Total cost of SCS treatment was 10,390€ for responder patients (RP) and 3181.11€ for non-responders (NRP). Reimbursement for RP consists of 2 DRG 4 6.430€ and DRG 4 + DRG 461 (2797.13€) for NRP. The prostanoid pathway consists of one hospitalization lasting between 7 and 28 days. This hospitalization can be repeated if the clinical condition of the patient does not improve after the first cycle of treatment. The cost of this treatment varies from a minimum of 4445.73€ for a cycle of 7 days to a maximum of 9118.73€ for a 28 days cycle. Hospitalization for prostanoid therapy is reimbursed by DRG 130 (3524.82€) or by DRG 131 (2443.36€). CONCLUSIONS: SCS costs are fully covered by DRG while drug therapy costs are only partially covered. Besides, the treatments differ as regards to the ability to forecast patient total costs before starting treatment, which is low for prostanoid therapy and high for SCS therapy.